Multiplex Assays Global Market Report 2022

Multiplex Assays Global Market Report 2022 from The Business Research Company provides the strategists, marketers and senior management with the critical information they need to assess the global multiplex assays market.

This report focuses on multiplex assays market which is experiencing strong growth. The report gives a guide to the multiplex assays market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
• Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market research findings.
• Benchmark performance against key competitors.
• Utilize the relationships between key data sets for superior strategizing.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Where is the largest and fastest growing market for the multiplex assays? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Multiplex Assays market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider multiplex assays market, and compares it with other markets.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
• Market segmentations break down market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
• The multiplex assays market section of the report gives context. It compares the multiplex assays market with other segments of the multiplex assays market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, multiplex assays indicators comparison.

Scope

Markets Covered: 1) By Type: Nucleic Acid-Based Multiplex Assays; Protein-Based Multiplex Assays; Other Types

2) By Technology: Flow Cytometry; Luminescence; Fluorescence Detection; Multiplex Real-Time PCR; Other Technologies

3) By Application: Research And Development; Drug Discovery And Development; Biomarker Discovery And Validation; Clinical Diagnostic

4) By End User: Pharmaceutical And Biotechnology Companies; Hospitals And Research Institutes; Reference Laboratories; Other End Users

Companies Mentioned: Luminex Corporation; Thermo Fisher Scientific, Inc.; Illumina, Inc.; Bio-Rad Laboratories, Inc.; QIAGEN N.V

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Executive Summary

Major players in the multiplex assays market are Thermo Fisher Scientific, Inc., Luminex Corporation, Illumina, Inc, Bio-Rad Laboratories, Inc, QIAGEN N.V, Becton, Dickinson and Company, Buhlmann Laboratories, Seegene Inc, Meso Scale Diagnostics LLC., Randox Laboratories Ltd., Merck KGaA, Agilent Technologies, Inc., Quanterix, Bio-Techne Corporation, Promega Corporation, Hoffmann-La Roche, Siemens Healthineers, PerkinElmer, Inc., Danaher Corporation and Abbott Laboratories

The global multiplex assays market is expected to grow from $3.02 billion in 2021 to $3.25 billion in 2022 at a compound annual growth rate (CAGR) of 7.66%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $4.37 billion in 2026 at a CAGR of 7.67%.

The multiplex assay market consists of sales of immunoassays by entities (organizations, sole traders, or partnerships) in which multiple analytes (proteins, biomolecules, growth factors, cytokines, chemokines, and others) are penciled by detecting and quantifying them contemporaneously. These assays are used to amplify multiple targets in a polymerase chain response (PCR) trial and collect further information from nanosecond amounts of proteins or other analytes in lower time as compared to the conventional system, similar as ELISA. Multiplex assays are used for pathogen identification, mutation analysis, RNA discovery, gene discovery analysis, relation analysis, forensic studies, and others.

The main types of multiplex assays include nucleic acid-based multiplex assays, protein-based multiplex assays and other types. Nucleic acid-based multiplex assays are based on the nucleic acid to detect organism-specific DNA or RNA sequences. These tests are generally specific and highly sensitive and the results can be provided rapidly. The different multiplex assays technologies include flow cytometry, luminescence, fluorescence detection, multiplex real-time PCR and other technologies. Multiplex assays are used for various applications such as research and development, drug discovery and development, biomarker discovery and validation and clinical diagnostic by end-users including pharmaceutical and biotechnology companies, hospitals and research institutes, reference laboratories and other end users.

North America was the largest region in the multiplex assays market in 2021. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Increased incidence of chronic diseases is driving the growth of the global multiplex assay market. Multiplex assay is extensively used in clinical trials to analyze and study the efficacy of a disease and for detection of antibodies against those diseases. According to the World Health Organization (WHO) report published in April 2021, chronic diseases also known as non-communicable diseases (NCDs) kill 41 million people each year, equivalent to 71% of all deaths globally. Every year, between the ages of 30 and 69 years, more than 15 million people die from an NCD. Due to the growing acceptance and the advantages of multiplex assays over traditional assays such as quicker analysis, the market for multiplex assays is expected to develop rapidly, driving the growth in the forecast period.

Strategic partnerships and collaborations between companies in the industry is a trend gaining popularity in the multiplex assays market. Companies in the market are collaborating on developing assays that can detect diseases quickly and effectively. For instance, in 2020, China based biotechnology company, Sino Biological announces a co-development agreement with US based biotechnology company, Nanommune to jointly develop coronavirus antigen array products for serological studies of COVID-19 and other infectious diseases. The coronavirus multiplex serological assay collaboration allows Sino Biological to make its recombinant coronavirus antigens available on a microarray multiplex-based platform, which enables rapid profiling of antibodies interacting with these targets in biological samples.

In May 2021, Swiss healthcare company, Roche acquired GenMark for a deal amount of $1.8 billion. Through this acquisition, Roche's expands its portfolio of molecular diagnostics in syndromic testing. GenMark Diagnostics is a US based multiplex molecular diagnostic solutions provider, designed to enhance patient care, improve the key quality metrics, and reduce the total cost of care.

The countries covered in the multiplex assays market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.